CaringKind, New York’s leading organization in caring for Alzheimer’s disease and dementia patients for the past 30 years, has established an alliance with Cure Alzheimer’s Fund, a not-for-profit organization funding research to prevent, stop, or reverse the neurodegenerative disease. With the new alliance, people who contact CaringKind to find…
Muses Labs and Metabolon announced they have entered into a partnership to assess the application of metabolomics in people with early symptoms of cognitive decline and Alzheimer’s disease (AD). Metabolomics measures changes in levels of metabolites (small molecules) and maps them to specific biochemical pathways to give clinicians a…
NeuroVision Imaging has raised $10 million in new funding through a Series B financing round, led by a $5 million investment from Wildcat Capital Management. The funds will support NeuroVision’s research on retinal imaging technology, a potential new approach to amyloid detection in Alzheimer’s disease (AD). A particular…
New York City-based Intra-Cellular Therapies has started its ITI-007-201 Phase 3 clinical trial for the treatment of agitation in patients with dementia, including Alzheimer’s disease, following the company’s communication with the U.S. FDA. Intra-Cellular Therapies Chairman and CEO Dr. Sharon Mates said in a press release she is pleased that…
In an effort to promote education about Alzheimer’s disease and help local communities plan for this emerging public health crisis, Eli Lilly and Company has started an expansion of its “Community Conversations on Alzheimer’s” series with a panel discussion at the U.S. Conference of Mayors June 24-27 in Indianapolis.
Muses Labs has partnered with the George Washington Center for Integrative Medicine (GWCIM) to offer Alzheimer’s disease (AD) patients in the Washington, D.C. area the MEND Protocol (Metabolic Enhancement for Neuro-Degeneration), a comprehensive adherence program supporting patients and their caregivers that helps to improve patient outcomes. The MEND…
The U.S. Senate Appropriations Committee has forwarded a draft bill that could deliver nearly $1.4 billion in federal funds to Alzheimer’s disease (AD) research in 2017. In all health concerns related to the proposed bi-partisan bill, lawmakers recommend $34 billion – a $2 billion increase over fiscal year 2016 – to the…
Swedish researchers demonstrated that a heart medication can reduce the build-up of plaque in brain blood vessels in mice. If findings in this animal study hold true for humans, scientists may be closer to developing a drug against Alzheimer’s disease (AD). The study, “Platelets contribute to amyloid-β aggregation in cerebral…
The Alzheimer’s Association will use Alzheimer’s & Brain Awareness Month to debunk myths related to the disease, while raising awareness about some truths – including being open about how fatal the disease really is: Alzheimer’s disease (AD) is the sixth-leading cause of death in the U.S. and the only one among…
A new study led by biomedical scientists at Indiana University has revealed evidence that the NMNAT2 enzyme may be protective against the debilitating effects of certain degenerative disorders, including Alzheimer’s Disease. The study, “NMNAT2:HSP90 Complex Mediates Proteostasis in Proteinopathies,” was published in the journal…
Get regular updates to your inbox.